title: Update in Cystic Fibrosis 2014.
authors.affiliation: 1 Department of Pediatrics, University of Washington, Seattle, Washington.|2 Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital, Seattle, Washington; and.
authors.forename: Thida
authors.initials: T
authors.lastname: Ong
authors.affiliation: 1 Department of Pediatrics, University of Washington, Seattle, Washington.|3 Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.
authors.forename: Bonnie W
authors.initials: BW
authors.lastname: Ramsey
mesh_terms: D000627:Aminophenols / Q000627:therapeutic use; D000631:Aminopyridines / Q000627:therapeutic use; D052117:Benzodioxoles / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000235:genetics / Q000382:microbiology / Q000503:physiopathology; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D005819:Genetic Markers; D006801:Humans; D009079:Mucociliary Clearance / Q000502:physiology; D015363:Quinolones / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000627:Aminophenols; D000631:Aminopyridines; D052117:Benzodioxoles; D005819:Genetic Markers; D015363:Quinolones; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C545203:ivacaftor; C569105:lumacaftor